The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Original Article: EU Panel Recommends Olaparib Tablets for Ovarian Cancer, Regardless of BRCA Status